Drugs and Diagnostics for Hematological Disorders: Global Markets

Report Highlights

The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.

Report Includes

• 49 data tables and 44 additional tables
• An overview of the current and future global markets for drugs and diagnostics for hematological disorders
• Analyses of the global market trends, with market revenue data for 2021-2023, estimates for 2024, forecasts for 2029, and projected CAGRs through 2029
• Estimate of the current market size and revenue growth prospects, along with a market share analysis by segment, product, end user, drug type, and region
• Facts and figures pertaining to the market dynamics, current and emerging technologies, regulations, cancer incidence, and the impact of various macroeconomic factors
• A look at treatment strategies, such as hematological therapeutics and drugs, chemotherapy, radiotherapy and immunotherapy, as well as testing and screening methods for diagnosis
• Review of technological developments, product introductions, and other recent industry activity of the major players
• Discussion of sustainability trends and ESG developments in the industry, with a focus on consumer attitudes, companies’ ESG score rankings and their ESG practices
• An analysis of recent patents
• A look at the competitive landscape, including companies’ market shares, M&A activity and venture funding
• Profiles of the leading market players, including Danaher, Abbott, Sysmex Corp., Bristol Myers Squibb Co., and F. Hoffmann-La Roche Ltd.

Report Scope

This report covers the worldwide market for the drugs used to treat hematological disorders, as well as the devices and reagents used to diagnose these diseases. Based on product type, the diagnostic market for hematological disorders is divided into reagents & instruments and software. By end user, the market is segmented into hospitals, diagnostic labs, and others. On the basis of drug type, the drugs used to treat hematological disorders are divided into oncology drugs and non-oncology drugs.

The market is divided into four geographic regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029. The report also covers approved drugs, the pipeline analysis, innovative research, opportunities within the market, and profiles of leading companies.

The growing number of individuals with leukemia is the main reason for the market's growth and the development of more effective drugs.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Consulting Editor’s Credentials

Christian Goodwin, MD, MPH, is a resident physician at Duke University. He completed his undergraduate degree at the University of Virginia. He obtained his MPH at the University of Liverpool as a US-UK Fulbright Scholar while serving as a visiting researcher at the Palliative Care Institute Liverpool. He obtained his MD from the University of North Carolina as a Blanchard Scholar. Christian has expertise in health systems innovation, public health research, geriatrics, and psychiatry.